Status and phase
Conditions
Treatments
About
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that has spread to other organs.
Full description
This is a single arm, proof-of-concept study. Fifteen subjects with urothelial cancer interested in participation will sign a "tissue acquisition and vaccine preparation consent" after which tumor tissue will be obtained from either a surgical resection specimen or biopsy. Subjects are scheduled to undergo cystectomy or nephroureterectomy for invasive urothelial cancer may consent prior to, or within 6 weeks after, surgery. The tumor specimen will be submitted for genomic sequencing followed by neoantigen identification utilizing a computational pipeline. Peptides corresponding to these neoantigens will be prepared for the personalized vaccine product. Subjects eligible for the treatment phase of the protocol (i.e., after surgery in adjuvant patients and chemotherapy in metastatic patients) will receive atezolizumab every 3 weeks plus up to ten doses of PGV001 vaccination plus Poly-ICLC. The primary objectives will be to determine the feasibility and safety of administration of a personalized neoantigen-based vaccine (PGV001) plus atezolizumab in subjects with locally advanced or metastatic urothelial cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Written informed consent and HIPAA authorization for release of personal health information.
Age ≥ 18 years at the time of consent.
ECOG Performance Status of ≤ 1 within fourteen days of registration for protocol therapy.
Histological or cytological evidence of urothelial cancer of the bladder, urethra, ureter, or renal pelvis. Differentiation with variant histologies (e.g., squamous cell differentiated) or pure variant histologies will be permitted provided that the predominant histology is urothelial carcinoma.
Clinical disease state specific criteria:
Required laboratory values must be obtained within thirty days of consent.
ANC ≥ 1500 cells/µL
WBC counts > 2500/µL
Lymphocyte count ≥ 300/µL
Platelet count ≥ 100,000/µL
Hemoglobin ≥ 8.0 g/dL
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) with the following exception:
o Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled.
AST and ALT ≤ 3.0 x ULN with the following exception:
o Patients with liver involvement: AST and/or ALT ≤ 5 x ULN
Alkaline phosphatase ≤ 2.5 x ULN with the following exception:
o Patients with documented liver involvement or bone metastases: alkaline phosphatase ≤ 5 x ULN
Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 30 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation:
(140 - age) x (weight in kg) x (0.85 if female) / 72 x (serum creatinine in mg/dL)
INR and aPTT ≤ 1.5 x ULN o This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.
Exclusion criteria
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
Symptomatic CNS metastases and/or metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm) and/or history of intracranial hemorrhage or spinal cord hemorrhage
Pregnancy, lactation, or breastfeeding
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.
Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan
o History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection
Active tuberculosis
A known additional primary malignancy that is progressing or requires active treatment. Exceptions include cancers that have undergone potentially curative therapy.
Medication-Related Exclusion Criteria:
Please contact site for other inclusion/exclusion criteria.
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal